HomeCompareVMGRX vs MRK

VMGRX vs MRK: Dividend Comparison 2026

VMGRX yields 20.12% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VMGRX wins by $16.8K in total portfolio value
10 years
VMGRX
VMGRX
● Live price
20.12%
Share price
$21.92
Annual div
$4.41
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$73.5K
Annual income
$6,822.98
Full VMGRX calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — VMGRX vs MRK

📍 VMGRX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVMGRXMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VMGRX + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VMGRX pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VMGRX
Annual income on $10K today (after 15% tax)
$1,709.88/yr
After 10yr DRIP, annual income (after tax)
$5,799.53/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, MRK beats the other by $2,528.88/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VMGRX + MRK for your $10,000?

VMGRX: 50%MRK: 50%
100% MRK50/50100% VMGRX
Portfolio after 10yr
$65.2K
Annual income
$8,310.56/yr
Blended yield
12.75%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

VMGRX
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VMGRX buys
0
MRK buys
0
No recent congressional trades found for VMGRX or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVMGRXMRK
Forward yield20.12%2.76%
Annual dividend / share$4.41$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$73.5K$56.8K
Annual income after 10y$6,822.98$9,798.13
Total dividends collected$41.9K$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: VMGRX vs MRK ($10,000, DRIP)

YearVMGRX PortfolioVMGRX Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$12,712$2,011.63$11,206$366.19+$1.5KVMGRX
2$15,991$2,389.82$12,650$502.35+$3.3KVMGRX
3$19,920$2,809.72$14,407$694.19+$5.5KVMGRX
4$24,586$3,271.10$16,585$967.82+$8.0KVMGRX
5$30,080$3,773.10$19,342$1,363.89+$10.7KVMGRX
6$36,500$4,314.27$22,913$1,947.19+$13.6KVMGRX
7$43,947$4,892.57$27,662$2,823.89+$16.3KVMGRX
8$52,529$5,505.48$34,159$4,173.35+$18.4KVMGRX
9$62,356$6,150.05$43,337$6,308.80+$19.0KVMGRX
10$73,544$6,822.98$56,776$9,798.13+$16.8KVMGRX

VMGRX vs MRK: Complete Analysis 2026

VMGRXStock

This actively managed, mid-capitalization option invests primarily in the stocks of mid-size domestic companies that the fund’s investment managers believe have stronger earnings and revenue growth prospects than the average mid-cap company. Investors who are seeking exposure to the mid-cap arena of the U.S. stock market and who are willing to endure the volatility that can come from an investment in stocks may wish to consider this fund as an option for their portfolio.The Vanguard Mid-Cap Growth Fund changed investment managers on November 17, 2025. This may result in capital gains distributions, which could be taxable if you hold shares in a regular (taxable) account. Vanguard provides monthly updates on estimated realized and unrealized gains in the "Distributions" section of the fund’s website page.The expense ratio for Mid-Cap Growth Fund will increase from 33bps to 39bps, with a 5bp fee waiver, making the effective expense ratio 34bps.

Full VMGRX Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this VMGRX vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VMGRX vs SCHDVMGRX vs JEPIVMGRX vs OVMGRX vs KOVMGRX vs MAINVMGRX vs JNJVMGRX vs ABBVVMGRX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.